{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:57:27Z","timestamp":1791496647267,"version":"4.3.4"},"reference-count":31,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>The approval of pembrolizumab for treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair\u2013deficient (dMMR) advanced cancers has led to increased requests for MSI and\/or MMR immunoperoxidase (IPOX) testing. Diagnoses for patients with advanced-stage cancer are frequently made from cytology specimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To investigate the feasibility of using cell block (CB) preparations of effusions for MMR IPOX evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>Surgical pathology cases of colorectal and endometrial carcinomas with known MMR\/MSI status and matched effusions with available CBs were identified. Cell block sections were evaluated for adequacy and stained with MMR IPOX (MSH2, MSH6, MLH1, and PMS2). The CBs were reviewed, the number of tumor cells quantified, and MMR IPOX was interpreted as retained, lost, suboptimal, or noncontributory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>We identified 748 cases with MMR\/MSI testing on surgical specimens having matched effusions. Of these, 131 cases (17.5%) had an available CB and 53 were deemed adequate for MMR IPOX staining. MMR IPOX results between effusion CBs and surgical pathology specimens were concordant in 45 of 53 (85%), inconclusive in 6 of 53 (11%), and discordant in 2 of 53 (4%) cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>There was high concordance of MMR IPOX testing between cytologic and surgical specimens, with no false-positive and 2 false-negative CB results. Limited tumor cells, staining in cells indefinite as tumor, tumor staining heterogeneity, and lack of internal control staining were problematic in some cases. Our findings indicate that cytologic effusion specimens may be suitable substrates for MMR IPOX biomarker testing; however, inconclusive cases need to be interpreted with caution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2019-0398-oa","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T11:23:25Z","timestamp":1585567405000},"page":"46-54","source":"Crossref","is-referenced-by-count":15,"title":["Evaluating Mismatch Repair\/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy"],"prefix":"10.5858","volume":"145","author":[{"given":"Elizabeth M.","family":"Jacobi","sequence":"first","affiliation":[{"name":"The Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Jacobi is currently in the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene","family":"Landon","sequence":"additional","affiliation":[{"name":"The Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell R.","family":"Broaddus","sequence":"additional","affiliation":[{"name":"The Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Broaddus is currently in the Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinchita","family":"Roy-Chowdhuri","sequence":"additional","affiliation":[{"name":"The Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2020,3,30]]},"reference":[{"key":"2020122322292979300_i1543-2165-145-1-46-b01","doi-asserted-by":"crossref","unstructured":"Richman S. Deficient mismatch repair: read all about it [review]. Int J Oncol. 2015; 47(4): 1189\u2013 1202.","DOI":"10.3892\/ijo.2015.3119"},{"key":"2020122322292979300_i1543-2165-145-1-46-b02","doi-asserted-by":"crossref","unstructured":"Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016; 22(4): 813\u2013 820.","DOI":"10.1158\/1078-0432.CCR-15-1678"},{"key":"2020122322292979300_i1543-2165-145-1-46-b03","doi-asserted-by":"crossref","unstructured":"Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015; 372(26): 2509\u2013 2520.","DOI":"10.1056\/NEJMoa1500596"},{"key":"2020122322292979300_i1543-2165-145-1-46-b04","doi-asserted-by":"crossref","unstructured":"Kalyan A, Kircher S, Shah H, Mulcahy M, Benson A. Updates on immunotherapy for colorectal cancer. J Gastrointest Oncol. 2018; 9(1): 160\u2013 169.","DOI":"10.21037\/jgo.2018.01.17"},{"key":"2020122322292979300_i1543-2165-145-1-46-b05","doi-asserted-by":"crossref","unstructured":"Toh JWT, de Souza P, Lim SH, et al. The potential value of immunotherapy in colorectal cancers: review of the evidence for programmed death-1 inhibitor therapy. Clin Colorectal Cancer. 2016; 15(4): 285\u2013 291.","DOI":"10.1016\/j.clcc.2016.07.007"},{"key":"2020122322292979300_i1543-2165-145-1-46-b06","doi-asserted-by":"crossref","unstructured":"Chang L, Chang M, Chang HM, Chang F. Microsatellite instability: a predictive biomarker for cancer immunotherapy. Appl Immunohistochem Mol Morphol. 2018; 26(2): e15\u2013 e21.","DOI":"10.1097\/PAI.0000000000000575"},{"key":"2020122322292979300_i1543-2165-145-1-46-b07","doi-asserted-by":"crossref","unstructured":"Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline summary from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Clin Oncol. 2017; 13(5): 333\u2013 337.","DOI":"10.1200\/JOP.2017.022152"},{"key":"2020122322292979300_i1543-2165-145-1-46-b08","doi-asserted-by":"crossref","unstructured":"Longacre TA, Broaddus R, Chuang LT, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the endometrium. Arch Pathol Lab Med. 2017; 141(11): 1508\u2013 1512.","DOI":"10.5858\/arpa.2016-0450-CP"},{"key":"2020122322292979300_i1543-2165-145-1-46-b09","doi-asserted-by":"crossref","unstructured":"Hampel H. NCCN increases the emphasis on genetic\/familial high-risk assessment in colorectal cancer. J Natl Compr Canc Netw. 2014; 12(5 suppl): 829\u2013 831.","DOI":"10.6004\/jnccn.2014.0200"},{"key":"2020122322292979300_i1543-2165-145-1-46-b10","doi-asserted-by":"crossref","unstructured":"Heald B, Plesec T, Liu X, et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol. 2013; 31(10): 1336\u2013 1340.","DOI":"10.1200\/JCO.2012.45.1674"},{"key":"2020122322292979300_i1543-2165-145-1-46-b11","doi-asserted-by":"crossref","unstructured":"Mills AM, Liou S, Ford JM, Berek JS, Pai RK, Longacre TA. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol. 2014; 38(11): 1501\u2013 1509.","DOI":"10.1097\/PAS.0000000000000321"},{"key":"2020122322292979300_i1543-2165-145-1-46-b12","unstructured":"United States Food & Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. 2017. https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm560040.htm. Accessed July 7, 2018."},{"key":"2020122322292979300_i1543-2165-145-1-46-b13","doi-asserted-by":"crossref","unstructured":"da Cunha Santos G, Saieg MA. Preanalytic specimen triage: smears, cell blocks, cytospin preparations, transport media, and cytobanking. Cancer Cytopathol. 2017; 125(S6): 455\u2013 464.","DOI":"10.1002\/cncy.21850"},{"key":"2020122322292979300_i1543-2165-145-1-46-b14","doi-asserted-by":"crossref","unstructured":"Sauter JL, Grogg KL, Vrana JA, Law ME, Halvorson JL, Henry MR. Young investigator challenge: validation and optimization of immunohistochemistry protocols for use on cellient cell block specimens. Cancer Cytopathol. 2016; 124(2): 89\u2013 100.","DOI":"10.1002\/cncy.21660"},{"key":"2020122322292979300_i1543-2165-145-1-46-b15","doi-asserted-by":"crossref","unstructured":"Roy-Chowdhuri S, Goswami RS, Chen H, et al. Factors affecting the success of next-generation sequencing in cytology specimens. Cancer Cytopathol. 2015; 123(11): 659\u2013 668.","DOI":"10.1002\/cncy.21597"},{"key":"2020122322292979300_i1543-2165-145-1-46-b16","doi-asserted-by":"crossref","unstructured":"Graham RP, Kerr SE, Butz ML, et al. Heterogenous MSH6 loss is a result of microsatellite instability within MSH6 and occurs in sporadic and hereditary colorectal and endometrial carcinomas. Am J Surg Pathol. 2015; 39(10): 1370\u2013 1376.","DOI":"10.1097\/PAS.0000000000000459"},{"key":"2020122322292979300_i1543-2165-145-1-46-b17","doi-asserted-by":"crossref","unstructured":"Mojtahed A, Schrijver I, Ford JM, Longacre TA, Pai RK. A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas. Mod Pathol. 2011; 24(7): 1004\u2013 1014.","DOI":"10.1038\/modpathol.2011.55"},{"key":"2020122322292979300_i1543-2165-145-1-46-b18","doi-asserted-by":"crossref","unstructured":"Shia J, Tang LH, Vakiani E, et al. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 2009; 33(11): 1639\u2013 1645.","DOI":"10.1097\/PAS.0b013e3181b15aa2"},{"key":"2020122322292979300_i1543-2165-145-1-46-b19","doi-asserted-by":"crossref","unstructured":"Stelloo E, Jansen AML, Osse EM, et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann Oncol. 2017; 28(1): 96\u2013 102.","DOI":"10.1093\/annonc\/mdw542"},{"key":"2020122322292979300_i1543-2165-145-1-46-b20","doi-asserted-by":"crossref","unstructured":"O'Brien O, Ryan E, Creavin B, et al. Correlation of immunohistochemical mismatch repair protein status between colorectal carcinoma endoscopic biopsy and resection specimens. J Clin Pathol. 2018; 71(7): 631\u2013 636.","DOI":"10.1136\/jclinpath-2017-204946"},{"key":"2020122322292979300_i1543-2165-145-1-46-b21","doi-asserted-by":"crossref","unstructured":"Chapel DB, Yamada SD, Cowan M, Lastra RR. Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy\/curettage or hysterectomy specimens. Gynecol Oncol. 2018; 149(3): 570\u2013 574.","DOI":"10.1016\/j.ygyno.2018.04.005"},{"key":"2020122322292979300_i1543-2165-145-1-46-b22","doi-asserted-by":"crossref","unstructured":"Kumarasinghe AP, de Boer B, Bateman AC, Kumarasinghe MP. DNA mismatch repair enzyme immunohistochemistry in colorectal cancer: a comparison of biopsy and resection material. Pathology. 2010; 42(5): 414\u2013 420.","DOI":"10.3109\/00313025.2010.493862"},{"key":"2020122322292979300_i1543-2165-145-1-46-b23","doi-asserted-by":"crossref","unstructured":"Nambirajan A, Jain D. Cell blocks in cytopathology: an update. Cytopathology. 2018; 29(6): 505\u2013 524.","DOI":"10.1111\/cyt.12627"},{"key":"2020122322292979300_i1543-2165-145-1-46-b24","doi-asserted-by":"crossref","unstructured":"Bao F, Panarelli NC, Rennert H, Sherr DL, Yantiss RK. Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma. Am J Surg Pathol. 2010; 34(12): 1798\u2013 1804.","DOI":"10.1097\/PAS.0b013e3181f906cc"},{"key":"2020122322292979300_i1543-2165-145-1-46-b25","doi-asserted-by":"crossref","unstructured":"Kuan SF, Ren B, Brand R, Dudley B, Pai RK. Neoadjuvant therapy in microsatellite-stable colorectal carcinoma induces concomitant loss of MSH6 and Ki-67 expression. Hum Pathol. 2017; 63: 33\u2013 39.","DOI":"10.1016\/j.humpath.2017.02.003"},{"key":"2020122322292979300_i1543-2165-145-1-46-b26","doi-asserted-by":"crossref","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New Engl J Med. 2015; 373(1): 23\u2013 34.","DOI":"10.1056\/NEJMoa1504030"},{"key":"2020122322292979300_i1543-2165-145-1-46-b27","doi-asserted-by":"crossref","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015; 14(4): 847\u2013 856.","DOI":"10.1158\/1535-7163.MCT-14-0983"},{"key":"2020122322292979300_i1543-2165-145-1-46-b28","doi-asserted-by":"crossref","unstructured":"Watson N, Grieu F, Morris M, et al. Heterogeneous staining for mismatch repair proteins during population-based prescreening for hereditary nonpolyposis colorectal cancer. J Mol Diagn. 2007; 9(4): 472\u2013 478.","DOI":"10.2353\/jmoldx.2007.060162"},{"key":"2020122322292979300_i1543-2165-145-1-46-b29","doi-asserted-by":"crossref","unstructured":"Jung J, Kang Y, Lee YJ, et al. Comparison of the mismatch repair system between primary and metastatic colorectal cancers using immunohistochemistry. J Pathol Transl Med. 2017; 51(2): 129\u2013 136.","DOI":"10.4132\/jptm.2016.12.09"},{"key":"2020122322292979300_i1543-2165-145-1-46-b30","doi-asserted-by":"crossref","unstructured":"Haddad R, Ogilvie RT, Croitoru M, et al. Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases. Ann Surg Oncol. 2004; 11(11): 977\u2013 982.","DOI":"10.1245\/ASO.2004.03.585"},{"key":"2020122322292979300_i1543-2165-145-1-46-b31","doi-asserted-by":"crossref","unstructured":"Haraldsdottir S, Roth R, Pearlman R, Hampel H, Arnold CA, Frankel WL. Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis. Fam Cancer. 2016; 15(2): 253\u2013 260.","DOI":"10.1007\/s10689-015-9856-2"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/145\/1\/46\/2690027\/i1543-2165-145-1-46.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/145\/1\/46\/2690027\/i1543-2165-145-1-46.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:38:53Z","timestamp":1764790733000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/145\/1\/article-p46.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3,30]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2019-0398-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,30]]}}}